- Disease Analysis: Chronic Heart Failure$22,000.00Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, or structural disorders of the myocardium or valves.
- Head and Neck Cancer Disease Coverage Forecast and Market Analysis to 2024$22,000.00Head and neck cancers (HNCs) are defined as any cancer that begins in cells of the oral cavity, pharynx, nose, sinuses, or salivary glands. These cancers are grouped together due to historical similarities in etiology, disease presentation, and manifestation. The vast majority of these cases (90%), collectively referred to as squamous cell carcinomas of the head and neck (HNSCCs), appear in squamous epithelial cells lining the mucous membranes of these regions. The exception to this is salivary gland cancer, which can appear in any of the salivary glands’ diverse cell types.
- Disease Analysis: HR+/HER2- Breast Cancer$22,000.00Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is defined by the overexpression of estrogen or progesterone receptors, or both, and a lack of HER2 expression.
- Disease Analysis: Hepatitis C$22,000.00Hepatitis C is a liver disease caused by chronic infection with hepatitis C virus (HCV), a hepacivirus belonging to the Flaviviridae family. HCV infects hepatocytes and is the leading cause of cirrhosis and hepatocellular cancer (HCC). Approximately 15−45% of people infected with HCV will spontaneously clear the virus, but the remaining 55−85% will develop chronic HCV infection. For those chronically infected with HCV, the risk of cirrhosis increases by 15–30% within 20 years. As of 2016, it is estimated that 71 million people are chronically infected with HCV worldwide, with approximately 399,000 infected people dying each year from liver-related diseases. There are barriers to diagnosing HCV, with the most notable being that chronically infected individuals may appear asymptomatic until the advanced stages of the disease. However, once diagnosed, there are excellent treatment regimens available for both noncirrhotic and cirrhotic patients.
- Disease Analysis: Type 1 Diabetes$22,000.00Diabetes mellitus is a group of chronic endocrine disorders characterized by hyperglycemia due to insufficient levels of insulin, a hormone responsible for regulating blood sugar. Symptoms include excessive excretion of urine (polyuria), thirst (polydipsia), constant hunger, weight loss, vision changes, and fatigue. According to the World Health Organization (WHO), approximately 8.5% of adults had diabetes in 2014.
- Crohn’s Disease Forecast and Market Analysis to 2027$22,000.00Crohn’s disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active.
- Disease Analysis: Type 2 Diabetes$22,000.00
Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.
- Market Spotlight: Venous Thromboembolism (VTE)$1,318.00Venous thromboembolism (VTE) refers to the formation of a thrombus (blood clot) within a vein, which subsequently blocks blood flow. VTE is the third most common form of vascular disease following stroke and heart attack. Because VTE is associated with greater morbidity and mortality, early diagnosis and treatment is essential. The most common causes of VTE include cancer, recent surgery, hospitalization, and immobilization.
- Market Spotlight: Tuberculosis (TB)$1,318.00This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
- Market Spotlight: Cold Agglutinin Disease$1,318.00This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.